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o Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate of 
8% and the 3rd highest mortality rate of all cancers in Canada1
o PDAC is characterized by the increased proliferation of cancer associated 
fibroblasts (CAFs)2
o CAFs are a potential predictor of clinical outcome and therapeutic target3
o CAFs can categorized into myofibroblastic CAFs (myCAFs) and inflammatory 
CAFs (iCAFs)2,3
o It is unclear how CAF populations and the proportion of myCAFs differ 
between patients
o While an abundance of myCAFs correlates with poor prognosis, myCAF
depletion has also been shown to promote PDAC progression4
o Therefore, the heterogeneity of CAF populations require further investigation
Figure 1.  myCAFs (red) and iCAFs (blue) differ in protein expression and 
proximity to tumour cells. myCAFs have a greater expression of alpha smooth 
muscle actin (⍺SMA) and are found in closer proximity to cancer cells 
compared to iCAFs. 
HYPOTHESIS & OBJECTIVE
Hypothesis: Distinguishable differences in the CAF populations between patients 
can help predict PDAC progression and sensitivity therapy
Objective: Characterize CAFs from PDAC tumours to identify differences between 
patients.
METHODS
Figure 2. CAFs were isolated from samples obtained through endoscopic ultrasound 
(EUS) biopsies or surgical resection. Isolated CAFs were cultured in Dulbecco's 
Modified Eagle Medium (DMEM) with 2% PenStrep and 10% fetal bovine serum. 
Western blotting and immunofluorescent staining were then used to characterize 
the fibroblasts at various culture passages. 
CONCLUSION AND FUTURE DIRECTIONS
The results of these experiments identify heterogeneity in the proportion of ⍺SMA 
positive cells within a population and the level of ⍺SMA expression within a cell. 
While EUS 8 and EUS 10 appear to express similar amounts of ⍺SMA based on 
western blot analysis (Figure 4) immunofluorescent staining (Figure 5) reveals 
differences in the intensity and number of ⍺SMA positive cells. For example, a 
larger proportion (89.9%)of EUS 8 fibroblasts stain positive for ⍺SMA compared to 
EUS 10 (52.07%), but at lower levels. 
Identifying the characteristics of a patient’s CAFs could help inform diagnosis and 
therapy. CAFs may be a potential therapeutic target.
Future Directions:
1. Correlate the fibroblast population makeup with patient clinical outcomes
2. Determine the ratio or myCAFs to iCAFs using IL-6, an iCAF marker.
3. Perform global gene expression analysis to compare CAF populations within 
(single cell) and between patients
This work was made possible by the USRI program from the University of Western 
Ontario and Schulich School of Medicine and Dentistry. I would like to thank the 
Children’s Health Research Institute, Lawson Health Research Institute, Danielle 
Porplycia from the Baker Centre for Pancreatic Cancer and the members of the Pin 
Lab for their support and contribution.
References:
1. Canadian Cancer Statistics 2020
2. Harryvan, TJ, et al., J Clin Med, 2019. 8(11): 1989.
3. Öhlund, D, et al., J Exp Med, 2017. 214(3): 579-596
4. Mizutani, Y, et al., Cancer Res, 2019. 79: 5367-5381
Figures 1 and 2 were created with BioRender.com
REFERENCES & ACKNOWLEDGEMENTS
Sample Passage Number Method of collection % ⍺SMA positive*
EUS 6 4 EUS guided biopsy 28
EUS 7 2 EUS guided biopsy 88
EUS 8 12 EUS guided biopsy 90
EUS 10 5 EUS guided biopsy 52
EUS 15 3 EUS guided biopsy 79
231 2 Surgery 34
253 6 Surgery 87
272 2 Surgery 68
275 2 Surgery 35
*Percentages were determined through quantification of immunofluorescent 
staining (see Figure 5). Passage number and method of collection are shown.
Figure 3. Cultured cells exhibit 
morphology characteristic of 
CAFs. Samples were imaged 
using phase contrast 
microscopy. CAFs (arrow) 
from EUS 15 appear to grow 
more slowly to EUS 8. 






Figure 4. Patient samples express different amounts of the myCAF marker, ⍺SMA. 
(A) Western blot analysis for ⍺SMA, vimentin and tubulin (used as a loading 
control). (B) The ratio of ⍺SMA to vimentin was compared between CAF lines. The 
ratios were obtained through the densitometric analysis of the Western blots 
shown in A. EUS 15 and 253 displayed greater ratios of ⍺SMA to vimentin, which is 




Figure 5. Heterogeneity in patient CAF populations. Co-immunofluorescent 
staining of ⍺SMA (red) and vimentin (green) show different proportion of ⍺SMA+ 
CAFs (EUS 10 vs. 253) and different intensities of ⍺SMA accumulation (EUS 8 vs. 
EUS 15). Samples correspond to those in previous figure. White arrows indicate 
fibroblasts that do not express ⍺SMA. Magnification bars = 50 µm.
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Table 1. Percentage of ⍺SMA positive cells vary between patient samples. 
